At the intersection of medicine and governance, recent events have exposed a fragile infrastructure supporting the US pharmaceutical system. Regulatory agencies once viewed as technocratic strongholds now find themselves entangled in political reshuffling, leadership voids, and legal uncertainty.
The FDA’s inaction on vaccine approval, the FTC’s paralyzed insulin price lawsuit,
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day
